<DOC>
	<DOCNO>NCT03061630</DOCNO>
	<brief_summary>Previously-untreated , high-risk ( &gt; T3 and/or N+ ) muscle-invasive bladder cancer ( MIBC ) cisplatin 60 mg/m2 day 1 gemcitabine 1000 mg/m2 day 1 , 8 15 . On day 1</brief_summary>
	<brief_title>A Prospective Study Neoadjuvant Chemotherapy With Gemcitabine/Platinum Muscle-Invasive Locally-Advanced Urothelial Carcinoma Bladder</brief_title>
	<detailed_description>Screening number endow patient sign inform consent form . These screen number use 'Subject Identification Code '' along patient initial . Patients withdraw study retain screen number . New patient must always allot new screen number . The study population include chemotherapy-naïve adult high-risk MIBC . Patients meet inclusion criterion none exclusion criterion receive cisplatin 60 mg/m2 day 1 gemcitabine 1000 mg/m2 day 1 , 8 15 . On day 1 , adequate hydration antiemetic need . Study chemotherapy repeat every 4 week outpatient basis continue disease progression , unacceptable toxicity , deterioration clinical condition , patient refusal , 2 3 cycle , depend operation schedule . Patients see every 4 week . All study subject also eligible receive best supportive care ( BSC ) define standard supportive measure consider primary treatment disease study , include use growth factor ( i.e . G-CSF ) myelosuppression , bisphosphonates management skeletal metastasis , analgesic transfusion blood product . BSC provide discretion investigator .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Must age 20 year 2 . Must histologically cytologically proven UC bladder . 3 . Must histological evidence highrisk muscleinvasive disease ( i.e. , T2~ T4 ) clinically N+ disease . They must consider treatment option radical cystectomy . 4 . Must ECOG performance status 0 1 5 . Must life expectancy 6 month 6 . At least 2 week since last surgical procedure biopsy prior enrolment . Subjects must recover &lt; Grade 2 acute toxicity toxicity must deem irreversible investigator . 7 . Adequate marrow function without growth factor support transfusion dependency 8 . Adequate renal function serum creatinine 1.5 x ULN calculate creatinine clearance ≥ 60 mL/min use CockcroftGault MDRD formulas 9 . Adequate hepatic function 10 . Must agree use adequate method contraception patient sexually active , 12 week completion chemotherapy 11 . Written voluntary inform consent understood , sign date . 1 . Ongoing treatment anticancer agent contemplate protocol 2 . Radiologic find consistent metastatic disease 3 . Severe medical phychological illness preclude participation study , include history clinically relevant coronary artery disease myocardial infarction within last 3 year , ( NYHA ) grade III great congestive heart failure , cerebrovascular attack within prior year , current serious cardiac arrhythmia require medication except atrial fibrillation 4 . Nontolerable &gt; Grade 2 neuropathy evidence unstable neurological symptom within 4 week Cycle 1 Day 1 5 . Major surgery , diagnostic surgery transurethral resection , within 4 week prior Cycle 1 Day 1 , without complete recovery 6 . Double primary cancer site ( ) history malignancy , except cure one discretion investigator 7 . Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy . 8 . Subjects exhibit allergic reaction study treatment 9 . Concomitant disease condition could interfere conduct study , would , opinion Investigator , pose unacceptable risk subject study 10 . Subject legal incapacity limited legal capacity . Dementia significantly alter mental status would limit understand render informed consent compliance requirement protocol . Unwillingness inability comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>